Abstract
Molecular Tumour Boards (MTBs) were created with the purpose of supporting clinical decision making within precision medicine. Though these meetings are in use globally reporting often focuses on the small percentages of patients that receive treatment via this process and are less likely to report on, and assess, patients who do not receive treatment. A literature review was performed to understand patient attrition within MTBs and barriers to patients receiving treatment. A total of 54 papers were reviewed spanning a 6 year period from 11 different countries. 20% of patients received treatment through the MTB process. Of those that did not receive treatment the main reasons were no mutations identified (26%), no actionable mutations (22%) and clinical deterioration (15%). However, the data was often incomplete due to inconsistent reporting of MTBs with only 53% reporting on patients having no mutations, 48% reporting on presence of actionable mutations with no treatment options and 57% reporting on clinical deterioration. As patient attrition in MTBs is an issue which is very rarely alluded to in reporting, more transparent reporting is needed to understand barriers to treatment and integration of new technologies is required to process increasing omic and treatment data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the AstraZeneca iDECIDE Programme (grant no. 119106) awarded to Manchester Cancer Research Centre and Cancer Research UK (CRUK), Associazione Italiana per la Ricerca sul Cancro (AIRC) and Fundacion Cientifica Asociacion Espanola Contra el Cancer (FC AECC), via an Accelerator Award [A29374] through the CRUK Manchester Institute [C147/A25254].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
n/a
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This work was supported by the AstraZeneca iDECIDE Programme (grant no. 119106) awarded to Manchester Cancer Research Centre and Cancer Research UK (CRUK), Associazione Italiana per la Ricerca sul Cancro (AIRC) and Fundacion Científica – Asociacion Espanola Contra el Cancer (FC -AECC), via an Accelerator Award [A29374] through the CRUK Manchester Institute [C147/A25254].
Updates to discussion for clarity and robustness. Removal of a paper which has been retracted.
Data Availability
All data is included in the supplementary materials and via the full papers included in the references.
